Related references
Note: Only part of the references are listed.Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
K. Ted Thurn et al.
FUTURE ONCOLOGY (2011)
Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies
Kevin A. David et al.
CANCER BIOLOGY & THERAPY (2010)
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
Dana Rathkopf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epigenetics in cancer: Targeting chromatin modifications
Leigh Ellis et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Guillermo Garcia-Manero et al.
BLOOD (2008)
Gene microarray analysis of human renal cell carcinoma The effects of HDAC inhibition and retinoid treatment
Trisha S. Tavares et al.
CANCER BIOLOGY & THERAPY (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore et al.
CLINICAL CANCER RESEARCH (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R. Blumenschein et al.
INVESTIGATIONAL NEW DRUGS (2008)
Design of selective nuclear receptor modulators: RAR and RXR as a case study
Angel R. de Lera et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma
Ming Zhao et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2007)
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
Yukihiko Kato et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Epigenetic modulation of retinoic acid receptor β2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma
XF Wang et al.
CLINICAL CANCER RESEARCH (2005)
Retinoic acid and the histone deacetylase inhibitor trichostatin A inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model
SE Touma et al.
CLINICAL CANCER RESEARCH (2005)
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
JC Byrd et al.
BLOOD (2005)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
The promise of retinoids to fight against cancer
L Altucci et al.
NATURE REVIEWS CANCER (2001)
Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells
V Bovenzi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer
M Widschwendter et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells
SM Sirchia et al.
ONCOGENE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Orphan receptor COUP-TF is required for induction of retinoic acid receptor β, growth inhibition, and apoptosis by retinoic acid in cancer cells
BZ Lin et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
